{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T11:55:27Z","timestamp":1774266927493,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T00:00:00Z","timestamp":1600214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000056","name":"NINR","doi-asserted-by":"publisher","award":["RC1-NR011591"],"award-info":[{"award-number":["RC1-NR011591"]}],"id":[{"id":"10.13039\/100000056","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000056","name":"NINR","doi-asserted-by":"publisher","award":["5R01NR017853"],"award-info":[{"award-number":["5R01NR017853"]}],"id":[{"id":"10.13039\/100000056","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study describes individual cancer patients\u2019 nonuse of extended-release or long-acting (ER\/LA) opioids, including periods of gap between opioid doses taken.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Secondary analysis of a three-month observational study of prescribed ER\/LA opioids monitored using electronic pill caps.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Two outpatient oncology clinics of a large health system in the Mid-Atlantic region.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Inclusion was based on self-identified African Americans and whites, at least 18\u2009years old, diagnosed with solid tumors or multiple myeloma. For the current analysis, the additional inclusion criterion was prescription of an oral ER\/LA opioid for cancer pain to be taken around the clock.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The electronic monitoring period for each study participant was partitioned into intervals of days between days with one or more openings (using medication event monitoring systems) representing rates of ER\/LA opioid nonuse over consecutive days and over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the sample (N\u2009=\u2009109), two-thirds of the cancer patients had some nonuse of prescribed ER\/LA opioids, with one in four having nonuse during 31.5\u201387.5% of their electronic-monitoring periods. Nonuse over periods of five or more, six or more, and seven or more consecutive days occurred for 37.6%, 34.9%, and 30.3% of the participants, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>About one in three ambulatory cancer patients in this study had substantial gaps between days of ER\/LA opioid use, potentially resulting in risk of overdose depending upon the prescribed ER\/LA opioid type, dose, and length of the time the opioid was stopped and resumed at the previous dose. This phenomenon has received little to no attention in the opioid safety discourse.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/pm\/pnaa273","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T19:25:08Z","timestamp":1595445908000},"page":"687-693","source":"Crossref","is-referenced-by-count":4,"title":["Gaps in the Use of Long-Acting Opioids Within Intervals of Consecutive Days Among Cancer Outpatients Using Electronic Pill Caps"],"prefix":"10.1093","volume":"22","author":[{"given":"Salimah H","family":"Meghani","sequence":"first","affiliation":[{"name":"Department of Biobehavioral Health Sciences; New Courtland Center for Transitions and Health; Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia L","family":"Persico","sequence":"additional","affiliation":[{"name":"Valor Healthcare Kingston, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Fudin","sequence":"additional","affiliation":[{"name":"Samuel S. Stratton Department of Veterans Affairs Medical Center, Albany, New York, USA"},{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York, USA"},{"name":"Western New England University, Springfield, Massachusetts, USA"},{"name":"Remitigate Therapeutics, Delmar, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J","family":"Knafl","sequence":"additional","affiliation":[{"name":"The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"2021031817234308800_pnaa273-B1"},{"issue":"5","key":"2021031817234308800_pnaa273-B2","first-page":"xxiv","article-title":"CDC issues key clarification on guideline for prescribing opioids for chronic pain","volume":"17","year":"2019","journal-title":"J Natl Comprehen Cancer Netw"},{"key":"2021031817234308800_pnaa273-B3","year":"2016"},{"key":"2021031817234308800_pnaa273-B4","year":"2016"},{"issue":"21","key":"2021031817234308800_pnaa273-B5","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1002\/cncr.30839","article-title":"Cancer survivorship and opioid prescribing rates: A population-based matched cohort study among individuals with and without a history of cancer","volume":"123","author":"Sutradhar","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"2021031817234308800_pnaa273-B6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12094-016-1529-6","article-title":"Chronic opioid therapy in long-term cancer survivors","volume":"19","author":"Carmona-Bayonas","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"2021031817234308800_pnaa273-B7","year":"2018"},{"issue":"7","key":"2021031817234308800_pnaa273-B8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/AJP.0b013e31816fe020","article-title":"Prevalence rates for and predictors of self-reported adherence of oncology outpatients with analgesic medications","volume":"24","author":"Valeberg","year":"2008","journal-title":"Clin J Pain"},{"issue":"2","key":"2021031817234308800_pnaa273-B9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jpainsymman.2007.10.015","article-title":"Assessing analgesic regimen adherence with the Morisky medication adherence measure for Taiwanese patients with cancer pain","volume":"36","author":"Tzeng","year":"2008","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"2021031817234308800_pnaa273-B10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jpainsymman.2012.02.023","article-title":"Frequency and predictors of patient deviation from prescribed opioids and barriers to opioid pain management in patients with advanced cancer","volume":"45","author":"Nguyen","year":"2013","journal-title":"J Pain Symptom Manage"},{"issue":"9","key":"2021031817234308800_pnaa273-B11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jpain.2015.05.009","article-title":"Adherence to analgesics for cancer pain: A comparative study of African Americans and whites using an electronic monitoring device","volume":"16","author":"Meghani","year":"2015","journal-title":"J Pain"},{"issue":"2","key":"2021031817234308800_pnaa273-B12","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.pmn.2011.03.003","article-title":"A pilot study to identify correlates of intentional versus unintentional nonadherence to analgesic treatment for cancer pain","volume":"14","author":"Meghani","year":"2013","journal-title":"Pain Manag Nurs"},{"issue":"4","key":"2021031817234308800_pnaa273-B13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jpm.2012.0400","article-title":"A pilot study to investigate adherence to long-acting opioids among patients with advanced lung cancer","volume":"16","author":"Yoong","year":"2013","journal-title":"J Palliat Med"},{"issue":"1","key":"2021031817234308800_pnaa273-B14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jpainsymman.2018.10.491","article-title":"Factors related to adherence to opioids in black patients with cancer pain","volume":"57","author":"Yeager","year":"2019","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"2021031817234308800_pnaa273-B15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.jpainsymman.2019.02.023","article-title":"Patient patterns and perspectives on using opioid regimens for chronic cancer pain","volume":"57","author":"Wright","year":"2019","journal-title":"J Pain Symptom Manage"},{"key":"2021031817234308800_pnaa273-B16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2147\/PPA.S93726","article-title":"Patterns of analgesic adherence predict health care utilization among outpatients with cancer pain","volume":"10","author":"Meghani","year":"2016","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"2021031817234308800_pnaa273-B17","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10903-012-9582-x","article-title":"Assessment of pain and analgesic use in African American cancer patients: Factors related to adherence to analgesics","volume":"14","author":"Rhee","year":"2012","journal-title":"J Immigr Minor Health"},{"issue":"26","key":"2021031817234308800_pnaa273-B18","first-page":"563","article-title":"Vital signs: Variation among states in prescribing of opioid pain relievers and benzodiazepines - United States, 2012","volume":"63","author":"Paulozzi","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021031817234308800_pnaa273-B19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jsr.2014.09.001","article-title":"Variation among states in prescribing of opioid pain relievers and benzodiazepines\u2014United States, 2012","volume":"51","author":"Paulozzi","year":"2014","journal-title":"J Saf Res"},{"issue":"15","key":"2021031817234308800_pnaa273-B20","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2016.1464","article-title":"CDC guideline for prescribing opioids for chronic pain\u2013United States, 2016","volume":"315","author":"Dowell","year":"2016","journal-title":"JAMA"},{"issue":"11","key":"2021031817234308800_pnaa273-B21","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1111\/pme.12480","article-title":"Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients","volume":"15","author":"Zedler","year":"2014","journal-title":"Pain Med"},{"issue":"9","key":"2021031817234308800_pnaa273-B22","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jamainternmed.2015.3259","article-title":"Prescription opioid duration of action and the risk of unintentional overdose\u2014reply","volume":"175","author":"Miller","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"1","key":"2021031817234308800_pnaa273-B23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/pds.4572","article-title":"Opioid tolerance and clinically recognized opioid poisoning among patients prescribed extended-release long-acting opioids","volume":"28","author":"Young","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2021031817234308800_pnaa273-B24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp021113","article-title":"The neurobiology of opioid dependence: Implications for treatment","volume":"1","author":"Kosten","year":"2002","journal-title":"Sci Pract Perspect"},{"key":"2021031817234308800_pnaa273-B25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fphar.2014.00280","article-title":"Opioid receptor desensitization: Mechanisms and its link to tolerance","volume":"5","author":"Allouche","year":"2014","journal-title":"Front Pharmacol"},{"key":"2021031817234308800_pnaa273-B26","year":"2019"},{"issue":"2","key":"2021031817234308800_pnaa273-B27","first-page":"129","article-title":"Pain assessment: Global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"issue":"2","key":"2021031817234308800_pnaa273-B28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpainsymman.2006.10.019","article-title":"Preference for analgesic treatment for cancer pain among African Americans","volume":"34","author":"Meghani","year":"2007","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"2021031817234308800_pnaa273-B29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5306\/wjco.v8.i1.75","article-title":"Salient concerns in using analgesia for cancer pain among outpatients: A cluster analysis study","volume":"8","author":"Meghani","year":"2017","journal-title":"World J Clin Oncol"},{"issue":"4","key":"2021031817234308800_pnaa273-B30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/NCC.0000000000000284","article-title":"Managing one's symptoms: A qualitative study of low-income African Americans with advanced cancer","volume":"39","author":"Yeager","year":"2016","journal-title":"Cancer Nurs"},{"key":"2021031817234308800_pnaa273-B31","year":"2019"},{"key":"2021031817234308800_pnaa273-B32","first-page":"1","article-title":"Pharmacological considerations regarding equianalgesic dosing. A white paper from the Academy of Integrative Pain Management","author":"Fudin","year":"2017","journal-title":"Am Acad Integr Pain Manag"},{"issue":"3","key":"2021031817234308800_pnaa273-B33","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/15360288.2013.803512","article-title":"Potential P-glycoprotein pharmacokinetic interaction of telaprevir with morphine or methadone","volume":"27","author":"Fudin","year":"2013","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2021031817234308800_pnaa273-B34"},{"issue":"11","key":"2021031817234308800_pnaa273-B35","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/pm\/pnx245","article-title":"Short-acting opioids are associated with comparable analgesia to long-acting opioids in patients with chronic osteoarthritis with a reduced opioid equivalence dosing","volume":"19","author":"Ghodke","year":"2018","journal-title":"Pain Med"},{"issue":"3","key":"2021031817234308800_pnaa273-B36","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jpainsymman.2019.10.029","article-title":"When patients take charge of opioids: Self-management concerns and practices among cancer outpatients in the context of opioid crisis","volume":"59","author":"Meghani","year":"2020","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"2021031817234308800_pnaa273-B37","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1213\/ANE.0000000000002463","article-title":"Risk management for opioid prescribing in the treatment of patients with pain from cancer or terminal illness: Inadvertent oversight or taboo?","volume":"125","author":"Copenhaver","year":"2017","journal-title":"Anesth Analg"},{"issue":"1","key":"2021031817234308800_pnaa273-B38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0018578718779005","article-title":"A survey of opioid medication stewardship practices at academic medical centers","volume":"54","author":"Phelps","year":"2019","journal-title":"Hosp Pharm"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/22\/3\/687\/36641083\/pnaa273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/painmedicine\/article-pdf\/22\/3\/687\/36641083\/pnaa273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T17:24:48Z","timestamp":1616088288000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/22\/3\/687\/5906100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,16]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,9,16]]},"published-print":{"date-parts":[[2021,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnaa273","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"value":"1526-2375","type":"print"},{"value":"1526-4637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2020,9,16]]}}}